Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
Innovative TIMScore for dda-PASEF and dia-PASEF libraries, combined with TIMS DIA-NN identifies 9000 protein groups from 200 ng K562 lysate in just 35 min gradient
High level of vaccine efficacy maintained over a 6-month period of surveillance
Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments
Medicago and GSK collaborated on Covifenz, an adjuvanted plant-based vaccine
UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
100% efficacy against severe Covid-19 disease and hospitalizations
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
The first wave of shipments includes several countries, such as Germany, France and Austria
Subscribe To Our Newsletter & Stay Updated
